

Francesco P Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9157691/publications.pdf>

Version: 2024-02-01

183
papers

5,320
citations

87888

38
h-index

106344

65
g-index

202
all docs

202
docs citations

202
times ranked

6857
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
2	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. <i>Digestive and Liver Disease</i> , 2022, 54, 237-242.	0.9	20
3	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
4	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). <i>Journal of Hepatology</i> , 2022, 76, 364-370.	3.7	22
5	A prospective longitudinal assessment of <i>de novo</i> metabolic syndrome after liver transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14532.	1.6	7
6	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 500.	4.1	37
7	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	7.3	12
8	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
9	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. <i>Medicina (Lithuania)</i> , 2022, 58, 290.	2.0	6
10	COVID-19 and liver disease: where are we now?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 277-278.	17.8	19
11	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	3.7	43
12	HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist. <i>Journal of Hepatology</i> , 2022, , .	3.7	4
13	The Nuclear Receptor PXR in Chronic Liver Disease. <i>Cells</i> , 2022, 11, 61.	4.1	16
14	The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. <i>Biology</i> , 2022, 11, 693.	2.8	1
15	<i>Sars-Cov-2</i> vaccination in liver transplant recipients: The "holy grail" in a hostile environment. <i>Liver International</i> , 2022, 42, 1225-1228.	3.9	4
16	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
17	Transplant and Autoimmune Diseases. , 2021, , 281-293.		0
18	Therapeutic approaches for the treatment of aging-induced stem cell dysfunction. , 2021, , 223-230.		0

#	ARTICLE	IF	CITATIONS
19	A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection. <i>Transplant International</i> , 2021, 34, 756-757.	1.6	6
20	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
21	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
22	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	3.7	21
23	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
24	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	3
25	Hepatic benefits of HCV cure: Don't forget coagulation!. <i>Journal of Hepatology</i> , 2021, 74, 967-968.	3.7	5
26	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2
27	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , 2021, 13, 2274.	3.7	21
28	Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. <i>Pathology Research and Practice</i> , 2021, 221, 153451.	2.3	30
29	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	1.6	1
30	Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. <i>JHEP Reports</i> , 2021, 3, 100286.	4.9	19
31	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	3.9	13
32	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	3.9	29
33	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	4.3	16
34	New Indications for Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3867.	2.4	20
35	Recent Advances in the Management of Acute Variceal Hemorrhage. <i>Journal of Clinical Medicine</i> , 2021, 10, 3818.	2.4	12
36	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	3.7	15

#	ARTICLE	IF	CITATIONS
37	Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	0
38	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 349-357.	2.0	5
39	Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 775-782.	2.3	12
40	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, 26-37.	0.5	3
41	Transfusion-associated circulatory overload in gastroenterology. <i>Blood Transfusion</i> , 2021, 19, 197-204.	0.4	5
42	The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver. <i>Frontiers in Nutrition</i> , 2021, 8, 715183.	3.7	23
43	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, 4-10.	0.5	3
44	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. <i>Minerva Gastroenterology</i> , 2021, 67, 38-49.	0.5	0
45	Drug induced liver injury: from pathogenesis to liver transplantation. <i>Minerva Gastroenterology</i> , 2021, 67, 50-64.	0.5	1
46	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	3.9	12
47	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1188-1196.e3.	4.4	39
48	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
49	Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8874.	4.1	15
50	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.9	53
51	450 CLONAL DYNAMICS AND CELL-OF-ORIGIN OF NORMAL HEPATOCYTE EXPANSIONS IN HOMEOSTATIC HUMAN LIVERS AND THEIR ASSOCIATION WITH THE BILIARY EPITHELIUM. <i>Gastroenterology</i> , 2020, 158, S-1276.	1.3	0
52	Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. <i>Digestive and Liver Disease</i> , 2020, 52, e70-e71.	0.9	1
53	Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. <i>Journal of Clinical Medicine</i> , 2020, 9, 1353.	2.4	10
54	COVID-19 in Padua, Italy: not just an economic and health issue. <i>Nature Medicine</i> , 2020, 26, 806-806.	30.7	2

#	ARTICLE	IF	CITATIONS
55	Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DAAs-induced viral eradication. <i>Digestive and Liver Disease</i> , 2020, 52, e22.	0.9	0
56	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	3.7	38
57	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
58	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
59	Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 482-483.	3.7	3
60	Invasive fungal infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 7485-7496.	3.3	26
61	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.	1.0	2
62	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019, 71, 1106-1115.	3.7	69
63	PS-185-Magnetic resonance risk score and liver stiffness by transient elastography have complementary prognostic values in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e114.	3.7	0
64	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. <i>Journal of Hepatology</i> , 2019, 70, e234-e235.	3.7	1
65	Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. <i>Nutrients</i> , 2019, 11, 1602.	4.1	29
66	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. <i>Clinical Rheumatology</i> , 2019, 38, 2843-2850.	2.2	39
67	Young GI angle: A young point of view on translational medicine. <i>United European Gastroenterology Journal</i> , 2019, 7, 864-865.	3.8	1
68	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019, 11, 1568.	3.7	27
69	THU-071-Matrix modulation in chronic liver injury and resolution. <i>Journal of Hepatology</i> , 2019, 70, e190.	3.7	0
70	THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients. <i>Journal of Hepatology</i> , 2019, 70, e223-e224.	3.7	1
71	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	3.7	44
72	THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort. <i>Journal of Hepatology</i> , 2019, 70, e294.	3.7	0

#	ARTICLE	IF	CITATIONS
73	THU-444-Alteration of miRNAs expression in patients with HCV-related cirrhosis who developed HCC after therapy with DAAs. <i>Journal of Hepatology</i> , 2019, 70, e354.	3.7	0
74	GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival. <i>Journal of Hepatology</i> , 2019, 70, e84.	3.7	4
75	New Perspectives in Liver Transplantation: From Regeneration to Bioengineering. <i>Bioengineering</i> , 2019, 6, 81.	3.5	19
76	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 829-845.	6.7	28
77	The role of delta creatinine and serum albumin in predicting mortality in patients with severe alcoholic hepatitis and infection. <i>Digestive and Liver Disease</i> , 2019, 51, e29.	0.9	0
78	The role of alcoholic liver disease as risk factor for the development of de novo metabolic syndrome after liver transplantation: a prospective longitudinal study. <i>Digestive and Liver Disease</i> , 2019, 51, e51.	0.9	0
79	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	2.4	5
80	The administration of a high-fat diet alters bile acid composition and hepatic drug metabolism in rats. <i>Digestive and Liver Disease</i> , 2019, 51, e22.	0.9	0
81	De novo neoplasms after liver transplantation: donor gender and age influence. <i>Digestive and Liver Disease</i> , 2019, 51, e50.	0.9	0
82	Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform. <i>Digestive and Liver Disease</i> , 2019, 51, e16.	0.9	0
83	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1878-1885.	0.4	24
84	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.9	77
85	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019, 37, 255-266.	3.3	12
86	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019, 156, 96-107.e1.	1.3	82
87	Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 959-974.	1.2	12
88	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 376-377.	0.8	3
89	Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. <i>Liver International</i> , 2018, 38, 1770-1776.	3.9	10
90	When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. <i>Digestive and Liver Disease</i> , 2018, 50, 640-646.	0.9	59

#	ARTICLE	IF	CITATIONS
91	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. <i>Journal of Hepatology</i> , 2018, 69, 345-352.	3.7	128
92	Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. <i>Clinical Science</i> , 2018, 132, 255-272.	4.3	21
93	Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. <i>Liver International</i> , 2018, 38, 1316-1321.	3.9	9
94	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	3.7	51
95	The Efficacy of CMV Specific Immune Reconstitution is Highly Dependent on Donor/Recipient Serostatus and Type of Solid Organ Transplanted. <i>Transplantation</i> , 2018, 102, S334.	1.0	0
96	Organ Preservation in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2018, 38, 260-269.	3.6	23
97	Hemodynamic Evaluation of Nonselective β -Blockers in Patients with Cirrhosis and Refractory Ascites. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	5
98	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	3.9	39
99	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
100	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. <i>World Journal of Gastroenterology</i> , 2018, 24, 4403-4411.	3.3	31
101	Management of bacterial infection in the liver transplant candidate. <i>World Journal of Hepatology</i> , 2018, 10, 222-230.	2.0	14
102	Hepatitis B and liver transplantation. <i>Minerva Gastroenterology</i> , 2018, 64, 147-157.	0.5	2
103	HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A true-or-false game?. <i>Digestive and Liver Disease</i> , 2017, 49, 321-325.	0.9	5
104	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1853-1859.	2.4	27
105	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017, 49, 241-253.	0.9	23
106	Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 858-864.	2.0	11
107	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19
108	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	2.4	46

#	ARTICLE	IF	CITATIONS
109	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.9	0
110	Outcome of liver transplant recipients after the first episode of bacterial infection. <i>Digestive and Liver Disease</i> , 2017, 49, e12.	0.9	0
111	Evolution of liver transplantation for alcoholic liver disease: A single center study. <i>Digestive and Liver Disease</i> , 2017, 49, e240.	0.9	0
112	Reply. <i>Liver Transplantation</i> , 2017, 23, 1630-1631.	2.4	0
113	Modeling cost-effectiveness and health gains of a universal versus prioritized hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	7.3	25
114	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	1.6	3
115	Heparanase and macrophage interplay in the onset of liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 14956.	3.3	46
116	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1168-1176.	2.0	21
117	Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000183.	2.7	9
118	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	2.5	42
119	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
120	Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. <i>World Journal of Gastroenterology</i> , 2017, 23, 2095.	3.3	14
121	Liver transplantation for viral hepatitis in 2015. <i>World Journal of Gastroenterology</i> , 2016, 22, 1570.	3.3	36
122	HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience. <i>Digestive and Liver Disease</i> , 2016, 48, e237.	0.9	0
123	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.9	0
124	Coronary microvascular dysfunction in patients with decompensated cirrhosis: Another tool for understanding cirrhotic cardiomyopathy?. <i>Digestive and Liver Disease</i> , 2016, 48, e59.	0.9	0
125	Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. <i>Transplant International</i> , 2016, 29, 694-697.	1.6	4
126	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , 2016, 29, 135-152.	1.6	12

#	ARTICLE	IF	CITATIONS
127	New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation. <i>Annals of Transplantation</i> , 2016, 21, 632-643.	0.9	5
128	Recent advances in understanding and managing liver transplantation. <i>F1000Research</i> , 2016, 5, 2895.	1.6	21
129	Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 253-259.	0.8	3
130	Umbilical cord mesenchymal stem cells modulate dextran sulfate sodium induced acute colitis in immunodeficient mice. <i>Stem Cell Research and Therapy</i> , 2015, 6, 79.	5.5	49
131	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	1.6	7
132	Risk Factors for Central Pontine and Extrapontine Myelinolysis After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1257-1264.	1.0	40
133	Markers of acute rejection and graft acceptance in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 1061.	3.3	57
134	Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 1097.	2.0	17
135	Hepatitis C virus infection in end-stage renal disease and kidney transplantation. <i>Transplant International</i> , 2014, 27, 877-891.	1.6	23
136	Adult Liver Stem Cells. <i>Pancreatic Islet Biology</i> , 2014, , 319-338.	0.3	0
137	Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. <i>Journal of Hepatology</i> , 2013, 58, 287-296.	3.7	99
138	Use of Grafts From Anti-HBcâ€“Positive Donors in Liver Transplantation: A 5-Year, Single-Center Experience. <i>Transplantation Proceedings</i> , 2013, 45, 2707-2710.	0.6	8
139	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. <i>Transplantation</i> , 2013, 95, 1528-1534.	1.0	17
140	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. <i>Acta Dermato-Venereologica</i> , 2012, 92, 411-415.	1.3	34
141	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. <i>Transplantation</i> , 2012, 94, 784-793.	1.0	45
142	Stem cells in liver failure. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 35-45.	2.4	34
143	Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury. <i>BMC Gastroenterology</i> , 2012, 12, 88.	2.0	58
144	Stem and progenitor cells in liver regeneration and repair. <i>Cytotherapy</i> , 2011, 13, 135-144.	0.7	44

#	ARTICLE	IF	CITATIONS
145	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186.	1.8	2
146	Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 974-976.	0.6	14
147	Risk Factors in Liver Retransplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2011, 43, 1110-1113.	0.6	28
148	Adherence in liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 760-770.	2.4	138
149	Therapeutic application of stem cells in gastroenterology: An up-date. <i>World Journal of Gastroenterology</i> , 2011, 17, 3870.	3.3	17
150	Sexual Dysfunction in Chronic Liver Disease: Is Liver Transplantation an Effective Cure?. <i>Transplantation</i> , 2010, 89, 1425-1429.	1.0	48
151	Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Annals of Surgical Oncology</i> , 2010, 17, 2290-2302.	1.5	66
152	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010, 42, 642-649.	0.9	42
153	Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1194-1196.	0.6	18
154	Fibrosis Progression and the Pros and Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver Transplantation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2223-2225.	0.6	10
155	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , 2009, 15, 619-628.	2.4	41
156	Study of the microcirculation in hDAF transgenic rat livers xenoperfused with human blood. <i>Xenotransplantation</i> , 2009, 16, 83-90.	2.8	2
157	Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1096-1098.	0.6	11
158	Experimental hepatology applied to stem cells. <i>Digestive and Liver Disease</i> , 2008, 40, 54-61.	0.9	9
159	HCV Histological Recurrence and Survival Following Liver Transplantation in Patients With and Without Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2008, 40, 1974-1975.	0.6	4
160	Prevalence of celiac disease in adult patients with refractory functional dyspepsia: Value of routine duodenal biopsy. <i>World Journal of Gastroenterology</i> , 2008, 14, 6948.	3.3	36
161	Algorithm for Prioritization of Patients on the Waiting List for Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1855-1856.	0.6	4
162	Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 71-75.	1.4	41

#	ARTICLE	IF	CITATIONS
163	Bone marrow cells in the liver: Diverse cells, diverse effects. <i>Hepatology</i> , 2007, 46, 604-605.	7.3	3
164	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 821-829.	2.0	49
165	The Bone Marrow Functionally Contributes to Liver Fibrosis. <i>Gastroenterology</i> , 2006, 130, 1807-1821.	1.3	467
166	The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. <i>Hepatology</i> , 2006, 43, 316-324.	7.3	132
167	Galectin-3 regulates myofibroblast activation and hepatic fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5060-5065.	7.1	539
168	Expression of Matrix Metalloproteinases and Their Specific Inhibitors in Normal and Different Human Thyroid Tumor Cell Lines. <i>Thyroid</i> , 2004, 14, 881-888.	4.5	48
169	Understanding of and attitudes to xenotransplantation: a survey among Italian university students. <i>Xenotransplantation</i> , 2004, 11, 133-140.	2.8	36
170	Hepatic stem cells: from inside and outside the liver?. <i>Cell Proliferation</i> , 2004, 37, 1-21.	5.3	145
171	A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. <i>Gastroenterology</i> , 2004, 126, 955-963.	1.3	405
172	Acellular liver matrix improves the survival and functions of isolated rat hepatocytes cultured in vitro. <i>International Journal of Molecular Medicine</i> , 2004, 14, 511-5.	4.0	17
173	The role of the steatosis of the donor graft on histological features after liver transplantation (LT). <i>Gastroenterology</i> , 2003, 124, A691.	1.3	0
174	New insight in the biologic support of rat hepatocytes in primary culture. <i>Gastroenterology</i> , 2003, 124, A123.	1.3	0
175	Iodine supplementation restores fertility of sheep exposed to iodine deficiency. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 1081-1087.	3.3	24
176	Induction of Apoptosis by 1,4-Benzothiazine Analogs in Mouse Thymocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 1053-1062.	2.5	12
177	Homologous acellular matrix (HAM): a new support for hepatocyte culture. <i>Journal of Hepatology</i> , 2002, 36, 218-219.	3.7	51
178	Apoptotic Effects of Selected Strains of Lactic Acid Bacteria on a Human T Leukemia Cell Line Are Associated With Bacterial Arginine Deiminase and/or Sphingomyelinase Activities. <i>Nutrition and Cancer</i> , 2001, 40, 185-196.	2.0	58
179	Functional and morphological graft monitoring after liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 17-23.	1.1	13
180	Physiological and clinical implications of proANP(1-98) circulating levels in the perioperative phase of liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 39-48.	1.1	5

#	ARTICLE	IF	CITATIONS
181	GH/GHBP changes in the perioperative course of liver transplantation: pathophysiologic and clinical implications. Transplantation Proceedings, 2001, 33, 1390-1392.	0.6	1
182	Natural $\hat{\pm}$ -IFN in HCV recurrence after liver transplantation. Transplantation Proceedings, 2001, 33, 1457-1458.	0.6	8
183	Histological features of donor grafts for orthotopic liver transplantation. Transplantation Proceedings, 2001, 33, 1177-1178.	0.6	1